Trial Profile
Characterization of Myocardial Blood Flow Measurements Using Lexiscan (Regadenoson) (Lexiscan) Rubidium-82 Myocardial Perfusion PET: A Temporal-Dependency Investigation
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Regadenoson (Primary) ; Rubidium chloride
- Indications Coronary disorders
- Focus Diagnostic use; Pharmacodynamics
- 26 Jul 2016 Status changed from recruiting to completed.
- 27 Jul 2015 According to the ClinicalTrials.gov record, planned end date changed from 1 Sep 2015 to 1 Jan 2016.
- 27 Jul 2015 According to the ClinicalTrials.gov record, planned primary completion date changed from 1 Sep 2015 to 1 Jan 2016.